| scholarly article | Q13442814 |
| P2093 | author name string | Melissa A Smith | |
| Daniel O Villarreal | |||
| Linda A Snyder | |||
| Diana Chin | |||
| Leopoldo L Luistro | |||
| P2860 | cites work | Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma | Q24618690 |
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| Modulation of GITR for cancer immunotherapy | Q26853557 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| Restoring function in exhausted CD8 T cells during chronic viral infection | Q28289222 | ||
| The immune contexture in human tumours: impact on clinical outcome | Q29620667 | ||
| Immunosuppressive strategies that are mediated by tumor cells | Q29636247 | ||
| GITR agonist enhances vaccination responses in lung cancer | Q30279074 | ||
| Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation | Q33573450 | ||
| Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs | Q33926200 | ||
| Features of responding T cells in cancer and chronic infection. | Q33941340 | ||
| TGF-β downregulates KLRG1 expression in mouse and human CD8(+) T cells | Q40899436 | ||
| Biological behavior of malignant melanoma cells correlated to their survival in vivo | Q41067629 | ||
| Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival | Q41489558 | ||
| Contribution of Pulmonary KLRG1high and KLRG1low CD8 T Cells to Effector and Memory Responses during Influenza Virus Infection | Q41719095 | ||
| Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. | Q44480757 | ||
| Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. | Q45343706 | ||
| Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells | Q52004225 | ||
| Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--response | Q56897109 | ||
| Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidity T-Cell Responses against Poorly Immunogenic Tumors | Q61851543 | ||
| Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts | Q71148644 | ||
| The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? | Q79990209 | ||
| Solid tumors "melt" from the inside after successful CD8 T cell attack | Q82133126 | ||
| Tumor antigen expression in melanoma varies according to antigen and stage | Q82506715 | ||
| CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes | Q84474625 | ||
| The Alarmin HMGN1 contributes to antitumor immunity and is a potent immunoadjuvant | Q85282087 | ||
| Multicolor flow cytometric analysis of immune cell subsets in tumor-bearing mice | Q86426765 | ||
| Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity | Q34033407 | ||
| Transcriptional control of effector and memory CD8+ T cell differentiation | Q34064074 | ||
| Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired | Q34080914 | ||
| Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients | Q34161579 | ||
| Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity | Q34554995 | ||
| GITR/GITRL: more than an effector T cell co-stimulatory system. | Q34615533 | ||
| KLRG1+NKG2A+ CD8 T Cells Mediate Protection and Participate in Memory Responses during γ-Herpesvirus Infection | Q35157498 | ||
| Similarities and differences in CD4+ and CD8+ effector and memory T cell generation | Q35207085 | ||
| Molecular regulation of effector and memory T cell differentiation | Q35283304 | ||
| Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. | Q35527105 | ||
| Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans | Q35669097 | ||
| In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor | Q36229738 | ||
| Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma | Q36371068 | ||
| Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. | Q36403529 | ||
| Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo | Q36433183 | ||
| Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity | Q36459336 | ||
| Immune resistance orchestrated by the tumor microenvironment | Q36593747 | ||
| Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion | Q36745336 | ||
| Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity | Q36757129 | ||
| Effector-like CD8+ T Cells in the Memory Population Mediate Potent Protective Immunity | Q36988106 | ||
| Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies | Q37125759 | ||
| The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. | Q37308863 | ||
| Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma | Q37333645 | ||
| Memory CD8+ T cells exhibit increased antigen threshold requirements for recall proliferation | Q37576718 | ||
| Harnessing the immune response to treat cancer | Q37790599 | ||
| Key roles of adjuvants in modern vaccines | Q38169040 | ||
| Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy | Q38214095 | ||
| Trafficking of T cells into tumors | Q38283501 | ||
| Evolving synergistic combinations of targeted immunotherapies to combat cancer. | Q38553010 | ||
| Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy | Q38719468 | ||
| Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist | Q39030036 | ||
| A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist | Q39030631 | ||
| IL-21 Is Important for Induction of KLRG1+ Effector CD8 T Cells during Acute Intracellular Infection | Q39268381 | ||
| CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells | Q40266751 | ||
| Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. | Q40278217 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 39117-39130 | |
| P577 | publication date | 2017-03-27 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity | |
| P478 | volume | 8 |
| Q57191719 | Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects |
| Q45064262 | TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines |
| Q47185561 | Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment |
| Q55712193 | The Imbalance of FOXP3/GATA3 in Regulatory T Cells from the Peripheral Blood of Asthmatic Patients. |
| Q61811648 | Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses |
Search more.